CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1

CpG oligodeoxynucleotides, as a ligand of toll-like receptor (TLR)-9, have demonstrated promising antitumor effects in some clinical trials; however, its toxicity and low efficacy as a systemic therapy has limited its therapeutic applications. In order to improve its therapeutic efficacy, we investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Peng, Liu, Xin, Mansfield, Aaron S., Harrington, Susan M., Li, Yinghua, Yan, Yiyi, Dong, Haidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342548/
https://www.ncbi.nlm.nih.gov/pubmed/27602959
http://dx.doi.org/10.18632/oncotarget.11833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342548/
https://www.ncbi.nlm.nih.gov/pubmed/27602959
http://dx.doi.org/10.18632/oncotarget.11833

Ejemplares similares